


# COVID-19 Management PAXLOVID™ (nirmatrelvir/ritonavir) ELIGIBILITY ASSESSMENT for Community Prescribers

Paxlovid™ is an antiviral drug to treat **mild COVID-19** in people who have **tested positive** and have **symptoms**.

- Paxlovid™ prevents hospitalization and death in people who are at **high risk** of serious illness from COVID-19.
- Paxlovid™ does not seem to help people without risk factors. People without risk factors:
  - are unlikely to be hospitalized or die from COVID-19.
  - tend to recover without needing an antiviral medicine like Paxlovid™.
  - should be reassured that they do not need Paxlovid™ and offered symptom management.
- Paxlovid may cause side effects and has many potential drug interactions.

## ELIGIBILITY CRITERIA: Individuals must meet ONE of the ☐ criteria.

☐ **Moderately to severely immunocompromised** people are eligible regardless of age (≥18 years), vaccination status, and other risk factors. This includes:

- ☐ Active treatment for cancer\*    ☐ Stem cell transplant recipient\*    ☐ Immunocompromised due to medications → 
- ☐ Solid organ transplant recipient\*    ☐ Moderate or severe primary immunodeficiency\* (e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome)

Conditions other than those listed here do not meet the definition of moderately to severely immunocompromised for Paxlovid™ prescribing. Consider other risk factors.

\*Refer to appropriate specialist for Paxlovid™ prescribing—Cancer Clinic, Transplant Clinic, or Early COVID Therapeutics Team

### UNVACCINATED/UNDER-VACCINATED =received no doses or 1 dose of a 2-dose vaccine AND

- ☐ Age >55 years
- ☐ Age ≥18 years to <55 years with 1 or more risk factors

### VACCINATED =received 2 or more doses of a 2-dose vaccine or 1 dose of Janssen Jcovden (J&J) AND

- ☐ Age ≥70 years with 3 or more risk factors
- ☐ Age ≥70 years AND Indigenous with 2 or more risk factors
- ☐ Age ≥70 years AND residing in the North (NE1/2, NW 1, AHA) with 2 or more risk factors

Vaccination provides protection against hospitalization and death. People who are vaccinated may not need Paxlovid™ unless they have other risk factors.

### RISK FACTORS:

Total #: \_\_\_\_\_

- ☐ Body Mass Index (BMI) ≥30 kg/m<sup>2</sup>  
☐ Chronic kidney disease (eGFR ≥30mL/min to <60mL/min)  
☐ Cardiovascular or cerebrovascular disease (hypertension, coronary artery disease, congestive heart failure, congenital heart disease, cardiomyopathy, atrial fibrillation, hyperlipidemia, stroke)  
☐ Chronic lung disease (COPD, moderate to severe asthma, cystic fibrosis, pulmonary fibrosis, pulmonary hypertension)  
☐ Diabetes—Type 1 or 2  
☐ Neurodevelopmental disorders (e.g., cerebral palsy, Down syndrome) or other conditions that confer medical complexity (i.e., genetic or metabolic syndromes and severe congenital anomalies)  
☐ Sickle cell disease

## CONTRAINDICATIONS AND CAUTIONS:

- ☐ Hypersensitivity to nirmatrelvir, ritonavir, or any other components of the product  
☐ Longer than day 5 of symptoms but less than day 7  
☐ HIV and not currently on antiretroviral therapy or recent detectable viral load, AIDS-defining illness, CD4 count <200 mm<sup>3</sup>, or suspicion of uncontrolled HIV  
☐ eGFR <30 mL/min  
☐ Unmanageable drug interaction with nirmatrelvir/ritonavir

May be eligible for remdesivir  
→ Refer to Early COVID Therapeutics Team

- ☐ Symptoms of moderate to severe COVID-19  
☐ Previous COVID-19 infection and less than 90 days since symptoms have resolved  
☐ Longer than 7 days since symptom onset  
☐ Age <18 years old  
☐ Pregnant, breastfeeding, or unwilling to use effective contraception/abstinence while on therapy  
☐ Liver disease with severe hepatic impairment  
☐ Drug interaction with hydroxychloroquine/chloroquine, and/or strong inducers of CYP3A4 and p-glycoprotein

Not eligible for early COVID-19 antiviral →  
Emergency refer if needed +/- supportive care and symptom management